Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Total Non-Current Liabilities (2020 - 2025)

Puma Biotechnology's Total Non-Current Liabilities history spans 6 years, with the latest figure at $86.0 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 29.01% year-over-year to $86.0 million; the TTM value through Dec 2025 reached $86.0 million, down 29.01%, while the annual FY2025 figure was $86.0 million, 29.01% down from the prior year.
  • Total Non-Current Liabilities reached $86.0 million in Q4 2025 per PBYI's latest filing, down from $87.6 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $241.1 million in Q1 2021 to a low of $86.0 million in Q4 2025.
  • Average Total Non-Current Liabilities over 5 years is $165.0 million, with a median of $167.4 million recorded in 2023.
  • Peak YoY movement for Total Non-Current Liabilities: rose 2.13% in 2021, then crashed 42.32% in 2025.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $229.0 million in 2021, then fell by 15.69% to $193.1 million in 2022, then dropped by 8.34% to $177.0 million in 2023, then plummeted by 31.58% to $121.1 million in 2024, then dropped by 29.01% to $86.0 million in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Total Non-Current Liabilities are $86.0 million (Q4 2025), $87.6 million (Q3 2025), and $90.2 million (Q2 2025).